Ізраїль - іврит - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac

Ізраїль - іврит - Ministry of Health

novartis israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 50 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 150 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 50 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 150 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 150 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - קפסולה קשיחה - cysteamine as bitartrate 150 mg - mercaptamine

Ізраїль - іврит - Ministry of Health

tzamal bio-pharma ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 50 mg - quetiapine - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should